Apoptosis signal-regulating kinase inhibitor

Patent metadata

Field	Value
Publication number	US-9254284-B2
Application number	US-201414254342-A
Country	US
Kind code	B2
Filing date	Apr 16, 2014
Priority date	Jan 27, 2012
Publication date	Feb 9, 2016
Grant date	Feb 9, 2016

Abstract

The present invention relates to a compound of formula (I):

The compound has apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis.

First claim

What is claimed is:

1. A method of inhibiting apoptosis signaling-regulating kinase 1 comprising contacting an apoptosis signal-regulating kinase 1 with a composition comprising a compound of formula (I)

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the composition is a pharmaceutical composition comprising one or more pharmaceutically acceptable carriers.

3. The method of claim 2 , wherein the pharmaceutical composition is administered to a patient.

4. The method of claim 3 , wherein the pharmaceutical composition is administered orally.

5. The method of claim 4 , wherein the pharmaceutical composition is administered orally in tablets.

6. The method of claim 3 , wherein the pharmaceutical composition is administered in a single dosage.

7. The method of claim 3 , wherein the pharmaceutical composition is administered in multiple dosages.

8. The method of claim 3 , wherein the pharmaceutical composition is administered alone.

9. The method of claim 3 , wherein the pharmaceutical composition is administered in combination with one or more therapeutic agents.

10. The method of claim 9 , wherein the one or more therapeutic agents are selected from the group consisting of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, antihypertensive agents, antibiotic agents, analgesic agents, antidepressant agents, or antianxiety agents.

11. The method of claim 9 , wherein the pharmaceutical composition and the one or more therapeutic agents are administered simultaneously.

12. The method of claim 9 , wherein the pharmaceutical composition and the one or more therapeutic agents are administered one after the other within intervals.

Assignees

• Gilead Sciences Inc

Inventors

• Notte Gregory

Classifications

• A61P31/12

  Antivirals · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title